PharVision Advisers’s Zoetis ZTS Stock Holding History

PharVision Advisers’s Portfolio ZTS Stock Details ZTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,099	Closed	-$327K	–	821
2025 Q2	$327K	Buy	+2,099	New	+$333K	0.47%	62

Other funds holding ZTS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PharVision Advisers's ZTS Position: Q3 2025 in Review

PharVision Advisers sold out of Zoetis (ZTS) in Q3 2025, closing a stake of 2,099 shares — an estimated $327K sold.

PharVision Advisers first reported a position in ZTS in Q2 2025 and held it in 1 quarter. The position peaked at $327K in Q2 2025. 1,799 funds tracked by Wall St. Rank hold ZTS as of Q3 2025.

PharVision Advisers reported no remaining Zoetis position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 2,099 Zoetis shares in Q3 2025, an estimated $327K.
PharVision Advisers first reported a position in Zoetis in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Zoetis position peaked at $327K in Q2 2025.
1,799 funds tracked by Wall St. Rank held Zoetis as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.